drugset / Trial / NCT02775006
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
Phase 3
Terminated
45 enrolled
The Netherlands Cancer Institute
Dutch Society of Physicians for Pulmonology and Tuberculosis · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.
Timeline
- Start
- 2016-10-14
- Primary completion
- 2019-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Erlotinib | Small molecule | 150 mg | — |